Azitra (NYSEAMERICAN:AZTR) Issues Quarterly Earnings Results

Azitra (NYSEAMERICAN:AZTR) issued its earnings results on Tuesday. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.31, Zacks reports.

Azitra Stock Down 7.1 %

AZTR stock traded down $0.03 on Thursday, hitting $0.46. 188,711 shares of the company’s stock traded hands, compared to its average volume of 888,449. Azitra has a 1-year low of $0.43 and a 1-year high of $68.40. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.77 and a quick ratio of 0.77.

Azitra Company Profile

Azitra, Inc, an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease.